Description

Mycamine Powder for Solution for Infusions 100 mg. №1 Vial

Ingredients

Mycamine powder for solution for infusions contains 100 mg of micafungin sodium as the active ingredient.

Dosage

The recommended dosage of Mycamine for adults is 100 mg once daily administered by intravenous infusion over approximately 1 hour.

Indications

Mycamine is indicated for the treatment of invasive candidiasis, esophageal candidiasis, and invasive aspergillosis in patients who are refractory to or intolerant of other antifungal therapies.

Contraindications

Mycamine is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation.

Directions

Mycamine should be reconstituted with the appropriate diluent as directed before administration. It should not be mixed with or physically added to solutions containing other drugs.

Scientific Evidence

Studies have shown that Mycamine is effective in the treatment of invasive fungal infections. In a randomized controlled trial by Mora-Duarte et al., Mycamine demonstrated non-inferiority to caspofungin in treating candidemia and other invasive candidiasis.

Additional Information

It is important to monitor liver function tests during Mycamine therapy due to the potential for hepatotoxicity. Patients should be closely monitored for signs of anaphylaxis during administration.

Pharmacological Effects: Mycamine inhibits the synthesis of β-(1,3)-D-glucan, a key component of the fungal cell wall, leading to cell lysis and death. This mechanism of action makes it effective against a broad spectrum of fungal pathogens.

Clinical Trials: In a multicenter study by Ostrosky-Zeichner et al., Mycamine was found to be well-tolerated and effective in the treatment of esophageal candidiasis, with a favorable safety profile compared to fluconazole.